KEL
Kell blood group glycoprotein
Also known as: CD238, ECE3, KELL_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P23276
- Gene
- KEL
- Ensembl
- ENSG00000197993
- Chromosome
- 7
- Canonical length
- 732 aa
- Protein class
- Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Golgi apparatus,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a type II transmembrane glycoprotein that is the highly polymorphic Kell blood group antigen. The Kell glycoprotein links via a single disulfide bond to the XK membrane protein that carries the Kx antigen. The encoded protein contains sequence and structural similarity to members of the neprilysin (M13) family of zinc endopeptidases. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
732 residues, UniProt reviewed canonical sequence.
>P23276|KEL
1 MEGGDQSEEE PRERSQAGGM GTLWSQESTP EERLPVEGSR PWAVARRVLT AILILGLLLC
61 FSVLLFYNFQ NCGPRPCETS VCLDLRDHYL ASGNTSVAPC TDFFSFACGR AKETNNSFQE
121 LATKNKNRLR RILEVQNSWH PGSGEEKAFQ FYNSCMDTLA IEAAGTGPLR QVIEELGGWR
181 ISGKWTSLNF NRTLRLLMSQ YGHFPFFRAY LGPHPASPHT PVIQIDQPEF DVPLKQDQEQ
241 KIYAQIFREY LTYLNQLGTL LGGDPSKVQE HSSLSISITS RLFQFLRPLE QRRAQGKLFQ
301 MVTIDQLKEM APAIDWLSCL QATFTPMSLS PSQSLVVHDV EYLKNMSQLV EEMLLKQRDF
361 LQSHMILGLV VTLSPALDSQ FQEARRKLSQ KLRELTEQPP MPARPRWMKC VEETGTFFEP
421 TLAALFVREA FGPSTRSAAM KLFTAIRDAL ITRLRNLPWM NEETQNMAQD KVAQLQVEMG
481 ASEWALKPEL ARQEYNDIQL GSSFLQSVLS CVRSLRARIV QSFLQPHPQH RWKVSPWDVN
541 AYYSVSDHVV VFPAGLLQPP FFHPGYPRAV NFGAAGSIMA HELLHIFYQL LLPGGCLACD
601 NHALQEAHLC LKRHYAAFPL PSRTSFNDSL TFLENAADVG GLAIALQAYS KRLLRHHGET
661 VLPSLDLSPQ QIFFRSYAQV MCRKPSPQDS HDTHSPPHLR VHGPLSSTPA FARYFRCARG
721 ALLNPSSRCQ LWLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KEL can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 53 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 53 nTPM
- testis: 37 nTPM
- lymph node: 9.9 nTPM
- spinal cord: 6.4 nTPM
- tonsil: 6.3 nTPM
- spleen: 5.2 nTPM
Single-cell type
- oligodendrocytes: 33 nCPM
- erythrocyte progenitors: 29 nCPM
- sertoli cells: 23 nCPM
- megakaryocyte-erythroid progenitors: 6.5 nCPM
- renal connecting tubule cells: 6.4 nCPM
- esophageal suprabasal cells: 2.6 nCPM
Immune cell
- intermediate monocyte: 0.2 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 3 nTPM
- white matter: 3 nTPM
- thalamus: 2.6 nTPM
- medulla oblongata: 2.5 nTPM
- pons: 2.3 nTPM
- cerebral cortex: 1.9 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about KEL.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 136 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- KELL-NULL PHENOTYPE
- Kell blood group system
ReferencesPubMed · IEDB
Publications for KEL from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Type 1 Interferon Gene Signature Promotes RBC Alloimmunization in a Lupus Mouse Model.
2020 · Front Immunol · RCR 0.8 · 16 citations - Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.
2017 · Transfusion · RCR 0.3 · 6 citations - [Red blood cell antibody screening: error analysis in a french interlaboratory comparison program survey].
2006 · Transfus Clin Biol · RCR 0.1 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.09
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.65
- DepMap mean gene effect
- 0.13
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- establishment of localization in cell
- intracellular calcium ion homeostasis
- intracellular magnesium ion homeostasis
- myelination
- negative regulation of potassium ion transmembrane transport
- potassium ion transmembrane transport
- protein processing
- regulation of axon diameter
- regulation of cell size
- skeletal muscle fiber development
- vasoconstriction
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KEL as an antibody target. Whether an autoantibody or antibody against KEL could matter depends on whether native KEL is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KEL is annotated at the cell surface, where native KEL is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label KEL as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...